513 related articles for article (PubMed ID: 32424979)
21. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
22. TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change.
Payapilly A; Guilbert R; Descamps T; White G; Magee P; Zhou C; Kerr A; Simpson KL; Blackhall F; Dive C; Malliri A
Cell Rep; 2021 Nov; 37(6):109979. PubMed ID: 34758330
[TBL] [Abstract][Full Text] [Related]
23. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling.
Yu JJ; Zhou DD; Cui B; Zhang C; Tan FW; Chang S; Li K; Lv XX; Zhang XW; Shang S; Xiang YJ; Chen F; Yu JM; Liu SS; Wang F; Hu ZW; Hua F
Cancer Lett; 2020 Apr; 474():23-35. PubMed ID: 31931029
[TBL] [Abstract][Full Text] [Related]
24. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
25. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
[TBL] [Abstract][Full Text] [Related]
26. Chloroquine blocks the autophagic process in cisplatin-resistant osteosarcoma cells by regulating the expression of p62/SQSTM1.
Shen C; Wang W; Tao L; Liu B; Yang Z; Tao H
Int J Mol Med; 2013 Aug; 32(2):448-56. PubMed ID: 23722646
[TBL] [Abstract][Full Text] [Related]
27. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
[TBL] [Abstract][Full Text] [Related]
28. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
30. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
31. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
32. Casticin suppresses the carcinogenesis of small cell lung cancer H446 cells through activation of AMPK/FoxO3a signaling.
Gong Q; Cao X; Cao J; Yang X; Zeng W
Oncol Rep; 2018 Sep; 40(3):1401-1410. PubMed ID: 30015975
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer.
Yu J; Wang S; Zhao W; Duan J; Wang Z; Chen H; Tian Y; Wang D; Zhao J; An T; Bai H; Wu M; Wang J
Clin Cancer Res; 2018 May; 24(9):2148-2158. PubMed ID: 29437792
[No Abstract] [Full Text] [Related]
34. p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA.
Xu LZ; Li SS; Zhou W; Kang ZJ; Zhang QX; Kamran M; Xu J; Liang DP; Wang CL; Hou ZJ; Wan XB; Wang HJ; Lam EW; Zhao ZW; Liu Q
Oncogene; 2017 Jan; 36(3):304-317. PubMed ID: 27345399
[TBL] [Abstract][Full Text] [Related]
35. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
36. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
37. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
38. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
39. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
40. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.
Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W
Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]